MedTrace Logo

Management of Pruritus With Xyzal in Atopic Dermatitis

NCT00884325 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-08-16

Study results available
· View outcomes & findings →

Summary

It is historically well known that the management of pruritus in atopic dermatitis is very difficult. Most of the patients are not controlled with traditional antihistamines such as Clarinex, Claritin, and Allegra. It will be a welcome addition to our treatment armamentarium if a drug such as Xyzal can control pruritus associated with atopic dermatitis.

Conditions

Interventions

DRUG

Levocetirizine dihydrochloride (Xyzal)

One tablet 5 mg taken orally at night for 28 days

DRUG

placebo

One tablet taken orally at night for 28 days

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Derm Research, PLLC

    lead OTHER

Principal Investigators

  • Leon H. Kircik, M.D. · DermResearch, PLLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00884325 on ClinicalTrials.gov